Home
>
US Stocks
>
NEUROPACE INC

NEUROPACE INC (NPCE)

$4.5

[object Object]

([object Object]%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on NEUROPACE INC

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 10.2M → 14.47M (in $), with an average increase of 11.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -12.69M → -10.37M (in $), with an average increase of 7.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 23.9% return, outperforming this stock by 51.7%

Performance

  • $4.35
    $4.53
    $4.50
    downward going graph

    3.33%

    Downside

    Day's Volatility :3.87%

    Upside

    0.55%

    downward going graph
  • $1.22
    $6.50
    $4.50
    downward going graph

    72.89%

    Downside

    52 Weeks Volatility :81.23%

    Upside

    30.77%

    downward going graph

Returns

PeriodNEUROPACE INCSector (Health Care)Index (Russel 2000)
3 Months
-12.28%
0.3%
-6.7%
6 Months
179.5%
-6.1%
-3.7%
1 Year
-27.77%
-4.8%
-6.3%
3 Years
-81.97%
23.8%
26.9%

Highlights

Market Capitalization
114.3M
Book Value
$1.08
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.85
Wall Street Target Price
6.9
Profit Margin
-94.61%
Operating Margin TTM
-80.94%
Return On Assets TTM
-20.91%
Return On Equity TTM
-101.86%
Revenue TTM
48.6M
Revenue Per Share TTM
1.96
Quarterly Revenue Growth YOY
27.200000000000003%
Gross Profit TTM
32.5M
EBITDA
-39.1M
Diluted Eps TTM
-1.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.81
EPS Estimate Next Year
-1.63
EPS Estimate Current Quarter
-0.46
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    72%Buy
    18%Hold
    9%Sell
Based on 11 Wall street analysts offering stock ratings for NEUROPACE INC(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 53.33%

Current $4.50
Target $6.90

Company Financials

FY19Y/Y Change
Revenue
37.0M
-
Net Income
-30.0M
-
Net Profit Margin
-81.07%
-
FY20Y/Y Change
Revenue
41.1M
↑ 11.27%
Net Income
-24.3M
↓ 19.0%
Net Profit Margin
-59.02%
↑ 22.05%
FY21Y/Y Change
Revenue
45.2M
↑ 9.83%
Net Income
-36.1M
↑ 48.61%
Net Profit Margin
-79.85%
↓ 20.83%
FY22Y/Y Change
Revenue
45.5M
↑ 0.75%
Net Income
-47.1M
↑ 30.49%
Net Profit Margin
-103.43%
↓ 23.58%
Q4 FY21Q/Q Change
Revenue
11.0M
↑ 6.36%
Net Income
-36.1M
↑ 346.37%
Net Profit Margin
-328.09%
↓ 249.91%
Q1 FY22Q/Q Change
Revenue
11.4M
↑ 3.43%
Net Income
-11.5M
↓ 68.23%
Net Profit Margin
-100.76%
↑ 227.33%
Q2 FY22Q/Q Change
Revenue
10.2M
↓ 10.32%
Net Income
-12.7M
↑ 10.72%
Net Profit Margin
-124.41%
↓ 23.65%
Q3 FY22Q/Q Change
Revenue
11.2M
↑ 9.38%
Net Income
-11.8M
↓ 7.13%
Net Profit Margin
-105.63%
↑ 18.78%
Q4 FY22Q/Q Change
Revenue
12.8M
↑ 14.63%
Net Income
-11.1M
↓ 5.42%
Net Profit Margin
-87.15%
↑ 18.48%
Q1 FY23Q/Q Change
Revenue
14.5M
↑ 13.16%
Net Income
-10.4M
↓ 6.92%
Net Profit Margin
-71.69%
↑ 15.46%
FY19Y/Y Change
Total Assets
21.1M
-
Total Liabilities
150.4M
-
FY20Y/Y Change
Total Assets
56.0M
↑ 165.23%
Total Liabilities
203.8M
↑ 35.45%
FY21Y/Y Change
Total Assets
133.6M
↑ 138.72%
Total Liabilities
60.1M
↓ 70.53%
FY22Y/Y Change
Total Assets
114.1M
↓ 14.57%
Total Liabilities
79.3M
↑ 32.09%
Q4 FY21Q/Q Change
Total Assets
133.6M
↓ 5.45%
Total Liabilities
60.1M
↑ 0.86%
Q1 FY22Q/Q Change
Total Assets
129.0M
↓ 3.43%
Total Liabilities
66.2M
↑ 10.16%
Q2 FY22Q/Q Change
Total Assets
118.5M
↓ 8.09%
Total Liabilities
65.6M
↓ 0.78%
Q3 FY22Q/Q Change
Total Assets
120.5M
↑ 1.63%
Total Liabilities
77.1M
↑ 17.4%
Q4 FY22Q/Q Change
Total Assets
114.1M
↓ 5.29%
Total Liabilities
79.3M
↑ 2.94%
Q1 FY23Q/Q Change
Total Assets
106.3M
↓ 6.87%
Total Liabilities
78.8M
↓ 0.69%
FY19Y/Y Change
Operating Cash Flow
-25.0M
-
Investing Cash Flow
3.6M
-
Financing Cash Flow
21.4M
-
FY20Y/Y Change
Operating Cash Flow
-21.6M
↓ 13.65%
Investing Cash Flow
-10.8M
↓ 397.6%
Financing Cash Flow
55.0M
↑ 157.41%
FY21Y/Y Change
Operating Cash Flow
-24.6M
↑ 13.74%
Investing Cash Flow
-85.4M
↑ 693.13%
Financing Cash Flow
102.5M
↑ 86.38%
FY22Y/Y Change
Operating Cash Flow
-36.0
↓ 100.0%
Investing Cash Flow
23.8M
↓ 127.87%
Financing Cash Flow
0.0
↓ 100.0%
Q4 FY21Q/Q Change
Operating Cash Flow
-8.2M
↑ 85.42%
Investing Cash Flow
-154.0K
↓ 18.95%
Financing Cash Flow
911.0K
↑ 0.0%
Q1 FY22Q/Q Change
Operating Cash Flow
-11.4M
↑ 38.89%
Investing Cash Flow
-306.0K
↑ 98.7%
Financing Cash Flow
1000.0
↓ 99.89%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.7M
↓ 6.45%
Investing Cash Flow
8.2M
↓ 2791.5%
Financing Cash Flow
635.0K
↑ 63400.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-7.0M
↓ 34.56%
Investing Cash Flow
7.0M
↓ 15.38%
Financing Cash Flow
-8.0K
↓ 101.26%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.7M
↓ 133.41%
Investing Cash Flow
10.1M
-
Financing Cash Flow
-255.0K
↓ 59.39%

Technicals Summary

Sell

Neutral

Buy

NEUROPACE INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
NEUROPACE INC
NEUROPACE INC
-8.16%
179.5%
-27.77%
-81.97%
-81.97%
Stryker Corporation
Stryker Corporation
-9.11%
19.97%
16.24%
39.26%
58.16%
Boston Scientific Corp.
Boston Scientific Corp.
-3.3%
14.74%
24.51%
34.4%
69.07%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.33%
9.57%
-18.68%
9.48%
81.0%
Abbott Laboratories
Abbott Laboratories
-7.42%
-2.03%
-12.42%
8.38%
67.81%
Medtronic PLC
Medtronic PLC
-10.17%
6.51%
-18.66%
-17.37%
-4.6%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
NEUROPACE INC
NEUROPACE INC
NA
NA
NA
-1.81
-1.02
-0.21
0.0
1.08
Stryker Corporation
Stryker Corporation
39.65
39.65
2.85
10.16
0.16
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
91.11
91.11
2.53
1.95
0.05
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
35.05
35.05
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
24.81
24.81
18.76
4.4
16.03
0.06
0.02
21.28
Medtronic PLC
Medtronic PLC
18.2
18.2
3.04
5.28
7.81
0.04
0.03
38.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
NEUROPACE INC
NEUROPACE INC
Buy
$114.3M
-81.97%
NA
-94.61%
Stryker Corporation
Stryker Corporation
Buy
$103.4B
58.16%
39.65
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$74.7B
69.07%
91.11
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$49.7B
81.0%
35.05
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$177.6B
67.81%
24.81
13.98%
Medtronic PLC
Medtronic PLC
Buy
$111.1B
-4.6%
18.2
13.21%

Institutional Holdings

  • KCK Ltd

    22.16%

  • Orbimed Advisors, LLC

    15.82%

  • Soleus Capital Management, L.P.

    9.34%

  • Morgan Stanley - Brokerage Accounts

    8.63%

  • FMR Inc

    5.72%

  • Millennium Management LLC

    2.73%

Corporate Announcements

  • NEUROPACE INC Earnings

    NEUROPACE INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Organization
NEUROPACE INC
Employees
163
CEO
Mr. Michael L. Favet
Industry
Healthcare

Discover More

FAQs